Prostate-specific antigen bounce in patients treated before 60 years old by iodine 125 brachytherapy for prostate cancer is frequent and not a prognostic factor.

Fiche publication

Date publication

août 2018

Journal

Brachytherapy

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BERNIER-CHASTAGNER Valérie , Dr ESCHWEGE Pascal , Pr PEIFFERT Didier

Tous les auteurs :
Charret J, Baumann AS, Eschwege P, Moreau JL, Bernier V, Falk AT, Salleron J, Peiffert D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30172752

Résumé

The only prognostic factor of prostate-specific antigen (PSA) bounce in prostate cancer found in several studies is young age but has never been specifically studied in this subset of patients for long-term results. Bounce characteristics, histological, clinical, and dosimetric data in young patients were analyzed, as well as their impact on toxicity and survival.